36 episodes

Lupus Science and Medicine is a global, peer reviewed, Open Access, online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. It is the first lupus-specific Open Access journal in the world and was developed in response to the need for a barrier-free forum for publication of groundbreaking studies in lupus. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

Lupus Science and Medicine podcast BMJ Group

    • Science
    • 3.8 • 12 Ratings

Lupus Science and Medicine is a global, peer reviewed, Open Access, online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. It is the first lupus-specific Open Access journal in the world and was developed in response to the need for a barrier-free forum for publication of groundbreaking studies in lupus. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

    Using patient registries to estimate SLE incidence rate in the USA

    Using patient registries to estimate SLE incidence rate in the USA

    Duane Peters from the Lupus Foundation of America interviews Dr Peter Izmirly from New York University and Dr Elizabeth Ferucci from the Alaska Native Tribal Health Consortium, both in the USA.

    They discuss the establishment of a network of population-based lupus patient registries in the USA and how these have been used to estimate the incidence rate of systemic lupus erythematosus using standardised data stratified by sex, race and ethnicity.

    Access the article: https://lupus.bmj.com/content/8/1/e000614

    • 16 min
    Defining remission in systemic lupus erythematosus

    Defining remission in systemic lupus erythematosus

    Duane Peters from the Lupus Foundation of America interviews Professor Ronald van Vollenhoven from the Amsterdam University Medical Centers in the Netherlands and Dr Cynthia Aranow from the Feinstein Institute for Medical Research in New York, USA.

    They discuss the efforts of the DORIS international task force to agree on a single definition of remission in systemic lupus erythematosus, which they hope will ensure that clinicians, patients and researchers in the field are all working towards the same outcome.

    Access the article: https://lupus.bmj.com/content/8/1/e000538

    • 19 min
    What's the relationship between self-efficacy and quality of life in SLE patients?

    What's the relationship between self-efficacy and quality of life in SLE patients?

    Duane Peters from the Lupus Foundation of America talks to Dr Cristina Drenkard from Emory University and Dr Teresa Brady from Clarity Consulting and Communications, both based in Atlanta, USA.

    They discuss their paper on the relationship between levels of self-efficacy and health behaviours and outcomes in black women with SLE. Their study specifically evaluated the associations between age, educational level and depression in SLE patients and the degree of pain and fatigue they experienced. These findings may help predict who might benefit most from self-efficacy-enhancing interventions to improve quality of life.

    Access the article: https://lupus.bmj.com/content/9/1/e000566

    • 20 min
    Challenging but achievable: reaching Low Lupus Disease Activity State (LLDAS) in childhood-onset SLE

    Challenging but achievable: reaching Low Lupus Disease Activity State (LLDAS) in childhood-onset SLE

    Duane Peters from the Lupus Foundation of America talks to Dr Sylvia Kamphuis and Dr Javad Wahadat from the Erasmus Medical Center in Rotterdam in the Netherlands about aiming for a Low Lupus Disease Activity State (LLDAS) in children with systemic lupus erythematosus (SLE). They outline the difference between LLDAS and clinical remission (CR), and discuss how LLDAS may be a more achievable target for patients than CR that nevertheless still brings significant clinical benefits in terms of decreasing damage accrual and improving health-related quality of life.

    Access the paper here: https://lupus.bmj.com/content/8/1/e000571

    • 20 min
    Could a high fiber diet positively impact the gut microbiome of SLE patients?

    Could a high fiber diet positively impact the gut microbiome of SLE patients?

    Duane Peters from the Lupus Foundation of America interviews Professor Iryna Kulyk from Indiana University in the USA and Professor Martin Kriegel from the University of Münster in Germany and Yale University in the USA. They discuss their study, presented at the Lupus 21st Century conference in September 2021, on the influence of the consumption of resistant starch (a type of dietary fiber) on the composition of the gut microbiota of lupus patients.

    Access the abstract here: https://lupus.bmj.com/content/8/Suppl_2/A63.2.abstract

    • 15 min
    A new biomarker for cognitive dysfunction in SLE?

    A new biomarker for cognitive dysfunction in SLE?

    Duane Peters from the Lupus Foundation of America interviews Dr Erik Anderson and Dr Meggan Mackay from the Feinstein Institutes for Medical Research in New York in the USA. They discuss their study into imbalances in quinolinic acid and kynurenic acid levels in the brain in SLE patients, and propose that the ratio between these two metabolites could be used as a new biomarker or therapeutic target for cognitive dysfunction.

    Access the paper here: https://lupus.bmj.com/content/8/1/e000559

    • 16 min

Customer Reviews

3.8 out of 5
12 Ratings

12 Ratings

Top Podcasts In Science

Hidden Brain
Jordan Harbinger
Alie Ward
Vox
Sam Harris
PRX and Greater Good Science Center

You Might Also Like

Lupus Foundation of America
LupusCorner
The Gwen Alexander, Inc.
2022|Hetlena Johnson, The Lupus Liar
Michael Putman
The Curious Clinicians